January 24, 2022
Specialty Pharmacy SmartBrief
News for the specialty pharmacy industrySIGN UP ⋅   SHARE
 
Leading News
The specialty pharmacy market continues to expand with the release of new products and the growing numbers of patients with chronic conditions, and 90% of large hospitals operate their own specialty pharmacies. Each hospital system will need solutions to support patients on specialty medications, and the integrated delivery network model can result in improved patient outcomes and lower medical costs.
Full Story: Pharmacy Times (1/2022) 
LinkedIn Twitter Facebook Email
Are you tired of biased news stories?
1M+ daily readers escape the opinions reported by traditional media outlets by subscribing to the 1440 Daily Digest. 1440 (curated and edited by a scientist) scours 100+ news sources and delivers a just-the-facts news briefing to your inbox daily. Learn more!
ADVERTISEMENT:
Specialty Pharmacy Update
Scientists are working on a production method that would allow them to freeze-dry mRNA COVID-19 vaccines so that they can be stored and transported at room temperature. "Our goal is to develop a freeze-drying process that can be used for mRNA-based COVID-19 vaccines to make them more stable and extend their shelf life, as well as make them easier to transport, store and use," said Seongkyu Yoon, one of the lead scientists of the project.
Full Story: News Medical (1/21) 
LinkedIn Twitter Facebook Email
Pfizer CEO Albert Bourla said it would be better to have a COVID-19 vaccine booster once a year instead of every four to five months, something the company is already looking into. Bourla said Pfizer aims to seek approval for a revised COVID-19 vaccine to combat the Omicron variant, which they plan to mass produce possibly as soon as March.
Full Story: Reuters (1/22) 
LinkedIn Twitter Facebook Email
Bristol Myers Squibb said it will limit 340B discounts on all drugs dispensed at hospitals' contract pharmacies, except for its immunomodulatory imide drugs, effective March 1, making it the 12th drugmaker to do so. In a letter sent to hospitals, Bristol said it will only offer discounts to up to two contract pharmacies if the hospital does not have an in-house pharmacy.
Full Story: Healthcare Finance (1/19),  FierceHealthcare (1/19) 
LinkedIn Twitter Facebook Email
Legislation & Regulation
Robert Califf, President Joe Biden's nominee for FDA commissioner, agreed with other industry experts that confirmatory trial completion is key to the success of the FDA's accelerated approval program, and Califf said new legislation may be necessary to stimulate generation of confirmatory data. Speaking at a recent summit, Califf praised the program's design but said its biggest problem is "the failure to produce confirmatory evidence quickly and in a way that really gives us the information that we need as patients and clinicians to decide which treatments are most effective and in which order."
Full Story: Regulatory Focus (1/19) 
LinkedIn Twitter Facebook Email
The Biden administration has created the Pandemic Innovation Task Force, which it says will be responsible for preparing countermeasures against new coronavirus variants and future infectious disease threats. Established by the White House Office of Science and Technology Policy, the task force will focus on new therapies, vaccines, tests and other tools to combat pandemic threats, and it will be led by White House Science Adviser Eric Lander and HHS Assistant Secretary for Preparedness and Response Dawn O'Connell, according to officials with knowledge of the matter.
Full Story: Bloomberg Government (1/18) 
LinkedIn Twitter Facebook Email
The FDA is deliberating on limited authorization for some monoclonal antibody treatments that have not proven effective in combating the coronavirus' Omicron variant. The agency is expected to decide on whether it will control the use of antibody treatment developed by Eli Lilly and Co. and partner Regeneron after the NIH updated its guidelines advising clinics not to use these treatments for patients who have mild to moderate COVID-19 because of their diminished efficacy versus the Omicron variant.
Full Story: CNN (1/23) 
LinkedIn Twitter Facebook Email
Marker Therapeutics' investigational T-cell immunotherapy MT-601 was granted orphan drug status by the FDA. The T-cell immunotherapy was developed as a treatment for metastatic or advanced pancreatic adenocarcinoma.
Full Story: Healio (free registration)/HemOnc Today (1/22) 
LinkedIn Twitter Facebook Email
Sponsored content from The Wall Street Journal
Free to read exclusively for SmartBrief readers
Hot Topics
Trends & Technology
New COVID-19 cases declined in 19 states, Washington, D.C., and Puerto Rico for the week that ended Thursday, but weekly new case rates were up 11% in the Midwest, 2% in the South and 3% in Western states. The CDC reported Friday that the nationwide seven-day average for new COVID-19 cases fell 5% from the prior week to 744,616, while average daily deaths were down 0.3% to 1,749.
Full Story: Reuters (1/21),  Becker's Hospital Review (1/24) 
LinkedIn Twitter Facebook Email
Press ReleasesSponsored Content
  Packaging Technology Group (PTG) Launches Cold Chain Industry's First Extended-Duration Curbside Recyclable Shipper
Post a Press Release
Sharing Specialty Pharmacy SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy and share your personalized link:
smartbrief.com/nasp/?referrerId=eSriBJbAIQ
We must do extraordinary things. We have to. It would be absurd not to.
Dave Eggers,
writer, editor, publisher
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT NASP:
Home page | Membership | News | Annual Meeting
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, a division of Future US LLC ©
1100 13th St. NW, Suite 1000, Washington, DC 20005